Key technical assets of TeraImmune
1) Expansion of human regulatory T cells in vitro
2) Receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell)
Grant awards
1) SBIR phase 1 (NHLBI, NIH) in April 2018
- grant for small businesses, scientifically verified
2) PACT program (NHLBI, NIH) in November 2018
- service grant supporting overall process development of the cell manufacturing: establishment of standard operating procedure (SOP), QA/QC and regulatory service